Neuron Bio carries out the capital increase with a subscription of 1,021,712 new shares

As result of the capital increase with pre-emptive subscription rights that ended on 23 March, the number of subscribed shares consists of 1,021,712 shares amounting to € 1,021,712. Consequently, the share capital of Neuron Bio, S.A. amounts to € 9,346,712.

Funds raised will be used for the promotion and development of AlzTest®, the aid test for the diagnostic of Alzheimer’s disease developed by the company and in full commercialization stage, as well as for the implementation of R&D services for third parties in the “Cube of Ideas”, the new building from Neuron Bio located in the Granada Bio Science & Technology Park, in which the company will move in coming months.

In words of the Chairman of the company, Fernando Valdivieso, “The Neuron Bio team is pleased with the result of the capital increase and appreciates the trust shareholders and investors have placed in the company”.

Neuron Bio has invested over € 30 million in the creation of a powerful scientific structure, in the development and the MAB going public of its subsidiary Neol Bio, in the construction of new and modern biotechnological headquarters in Granada and in the generation of patents and diagnostic methods such as the AlzTest®.